Latest Content
Over the last decade, orphan drugs have consistently outpaced their non-orphan counterparts in growth. They’ve doubled their market share in global prescription drug sales, climbing from less than 10% in 2014 to nearly 20% today. This year, they’re...
Read More
Recent years have seen significant developments in the landscape of cell and gene therapies, with a notable increase in treatments available for rare and life-threatening diseases. These advancements come despite the generally high costs of research,...
Read More
As part of Evaluate’s partnership with Galen Growth, we bring you their latest report on Digital Health Innovation in US Health Systems, built using data from HealthTech Alpha.
In the vast and complex US healthcare system, it’s challenging for all types...
Read More
